BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25426619)

  • 1. Well differentiation and intact Smad4 expression are specific features of groove pancreatic ductal adenocarcinomas.
    Izumi S; Nakamura S; Mano S; Akaki S
    Pancreas; 2015 Apr; 44(3):394-400. PubMed ID: 25426619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancerization of the Pancreatic Ducts: Demonstration of a Common and Under-recognized Process Using Immunolabeling of Paired Duct Lesions and Invasive Pancreatic Ductal Adenocarcinoma for p53 and Smad4 Expression.
    Hutchings D; Waters KM; Weiss MJ; Wolfgang CL; Makary MA; He J; Cameron JL; Wood LD; Hruban RH
    Am J Surg Pathol; 2018 Nov; 42(11):1556-1561. PubMed ID: 30212393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 accumulation confers prognostic information in resectable adenocarcinomas with ductal but not with intestinal differentiation in the pancreatic head.
    Bergan A; Gladhaug IP; Schjolberg A; Bergan AB; Clausen OP
    Int J Oncol; 2000 Nov; 17(5):921-6. PubMed ID: 11029493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.
    Biankin AV; Morey AL; Lee CS; Kench JG; Biankin SA; Hook HC; Head DR; Hugh TB; Sutherland RL; Henshall SM
    J Clin Oncol; 2002 Dec; 20(23):4531-42. PubMed ID: 12454109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease.
    Pai RK; Beck AH; Mitchem J; Linehan DC; Chang DT; Norton JA; Pai RK
    Am J Surg Pathol; 2011 Feb; 35(2):228-34. PubMed ID: 21263243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma.
    Sopha SC; Gopal P; Merchant NB; Revetta FL; Gold DV; Washington K; Shi C
    Int J Clin Exp Pathol; 2013; 6(11):2476-86. PubMed ID: 24228110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
    Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
    Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ductal adenocarcinoma of the pancreas usually retained SMAD4 and p53 protein status as well as expression of epithelial-to-mesenchymal transition markers and cell cycle regulators at the stage of liver metastasis.
    Liszka L
    Pol J Pathol; 2014 Jun; 65(2):100-12. PubMed ID: 25119169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paraneoplastic Ma Antigen-Like 1 as a Potential Prognostic Biomarker in Human Pancreatic Ductal Adenocarcinoma.
    Kuwae Y; Kakehashi A; Wakasa K; Wei M; Yamano S; Ishii N; Ohsawa M; Wanibuchi H
    Pancreas; 2015 Jan; 44(1):106-15. PubMed ID: 25251443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion.
    Lenz J; Karasek P; Jarkovsky J; Muckova K; Dite P; Kala Z; Veselska R; Hermanova M
    J Gastrointestin Liver Dis; 2011 Dec; 20(4):389-96. PubMed ID: 22187705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicator of poor survival.
    Kamphues C; Bova R; Bahra M; Klauschen F; Muckenhuber A; Sinn BV; Warth A; Goeppert B; Endris V; Neuhaus P; Weichert W; Stenzinger A
    Pancreas; 2015 Mar; 44(2):296-301. PubMed ID: 25423555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixed ductal-endocrine carcinomas of the pancreas and ductal adenocarcinomas with scattered endocrine cells: characterization of the endocrine cells.
    Ohike N; Jürgensen A; Pipeleers-Marichal M; Klöppel G
    Virchows Arch; 2003 Mar; 442(3):258-65. PubMed ID: 12647216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of STAT1 and p21 proteins predicts pancreatic cancer progression and prognosis.
    Sun Y; Yang S; Sun N; Chen J
    Pancreas; 2014 May; 43(4):619-23. PubMed ID: 24658320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastric- and intestinal-type marker expression in invasive ductal adenocarcinoma of the pancreas.
    Takano Y; Ohike N; Tajiri T; Asonuma K; Harada K; Takahashi H; Morohoshi T
    Hepatobiliary Pancreat Dis Int; 2012 Aug; 11(4):424-8. PubMed ID: 22893471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas.
    Sasaki S; Yamamoto H; Kaneto H; Ozeki I; Adachi Y; Takagi H; Matsumoto T; Itoh H; Nagakawa T; Miyakawa H; Muraoka S; Fujinaga A; Suga T; Satoh M; Itoh F; Endo T; Imai K
    Oncol Rep; 2003; 10(1):21-5. PubMed ID: 12469138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
    Adsay NV; Basturk O; Cheng JD; Andea AA
    Semin Radiat Oncol; 2005 Oct; 15(4):254-64. PubMed ID: 16183479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.
    Yamada S; Fujii T; Shimoyama Y; Kanda M; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Nakao A; Kodera Y
    Pancreas; 2015 May; 44(4):660-4. PubMed ID: 25760429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.
    Petrushnko W; Gundara JS; De Reuver PR; O'Grady G; Samra JS; Mittal A
    HPB (Oxford); 2016 Aug; 18(8):652-63. PubMed ID: 27485059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Well-differentiated pancreatic ductal adenocarcinomas measuring ≤ 1 cm exhibit early features of tumor progression: a report of five lesions and a comparative study with advanced lesions.
    Izumi S; Nakamura S; Mano S; Onoda Y
    Surg Today; 2014 Nov; 44(11):2058-64. PubMed ID: 24297432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.